CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis

Company Overview

CNS Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing treatments for primary and metastatic cancers of the brain and central nervous system. The company’s research is centered on therapies designed to address the challenges of delivering effective medicines across the blood-brain barrier.

Its lead product candidate is berubicin, an anthracycline designed to penetrate the blood-brain barrier and target malignant brain tumors. CNS Pharmaceuticals has primarily investigated berubicin as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer with limited treatment options. The company’s activities have included clinical development and evaluation of berubicin’s safety and efficacy.

CNS Pharmaceuticals is based in Houston, Texas, and serves the global biopharmaceutical market through its drug-development programs and clinical research activities. The company was founded to advance novel therapies for central nervous system cancers and became a publicly traded company in 2020. Its leadership has included John Climaco, who has served as chief executive officer.

Key Stats

• Today's Range: $5.03 to $5.40
• 50-Day Range: $5.01 to $6.01
• 52-Week Range: $1.90 to $10.54
• Volume: 6,198 shs
• Average Volume: 3,103 shs
• Market Capitalization: $7.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

CNS Pharmaceuticals Stock Analysis - MarketRank™

CNS Pharmaceuticals scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

CNS Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

CNS Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CNS Pharmaceuticals is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CNS Pharmaceuticals is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CNS Pharmaceuticals has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.06% of the float of CNS Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

CNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CNS Pharmaceuticals has recently decreased by 69.75%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CNS Pharmaceuticals does not currently pay a dividend.

Dividend Growth

CNS Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.39

News Sentiment

CNS Pharmaceuticals has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for CNS Pharmaceuticals this week, compared to 1 article on an average week.

MarketBeat Follows

Only 1 people have added CNS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CNS Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.82% of the stock of CNS Pharmaceuticals is held by insiders.

Percentage Held by Institutions

14.02% of the stock of CNS Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/12/2026
• Next Earnings (Estimated): 11/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CNSP
• CIK: 1729427
• Web: www.cnspharma.com
• Phone: 800-946-9185
• Fax: N/A
• Employees: 8
• Year Founded: 2017

Profitability

• EPS (Trailing Twelve Months): ($23.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.85 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -204.25%
• Return on Assets: -141.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.86
• Quick Ratio: 5.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.29 per share
• Price / Book: 0.71

Miscellaneous

• Outstanding Shares: 1,460,000
• Free Float: 1,434,000
• Market Cap: $7.58 million
• Optionable: Not Optionable
• Beta: 3.10